MIRA
INFORM REPORT
|
Report Date : |
16.09.2008 |
IDENTIFICATION
DETAILS
|
Name : |
SAM-OH FARMACHEM CO., LTD. |
|
|
|
|
Registered Office : |
6th Fl., Samo Bldg., 751-10, Yeoksam 1-dong, Gangnam-gu, Seoul |
|
|
|
|
Country : |
Korea |
|
|
|
|
Date of Incorporation : |
03.30.1995 |
|
|
|
|
Com. Reg. No.: |
120-81-49437 |
|
|
|
|
Legal Form : |
Company Limited by Shares |
|
|
|
|
Line of Business : |
Brokerage of Other Commodity |
RATING &
COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
Basic
|
Company
Name |
SAM-OH FARMACHEM
CO., LTD. |
|
Registered Address |
751-10, Yeoksam 1-dong, Gangnam-gu, Seoul,
Korea |
|
Building |
6th Fl., Samo Bldg. |
|
Zip Code |
135-925 |
|
Tel |
+82-2-514-5691 |
|
Fax |
+82-2-514-5690 |
|
E-mail |
samoh@samohfarmachem.co.kr |
|
Website |
www.samohfarmachem.co.kr |
|
Trading Address |
6th Fl., Samo Bldg., 751-10, Yeoksam
1-dong, Gangnam-gu, Seoul, Korea |
|
Tel |
+82-2-514-5691 |
|
Fax |
+82-2-514-5690 |
|
Other Address |
1BL, Ma-705, Shihwa Industrial Complex,
1353-4, Jeongwang-dong ,Siheung-si, Gyeonggi-do, Korea |
|
Tel |
+82-31-498-0355 |
|
Fax |
+82-31-433-5690 |
|
Type |
Import |
|
Industry |
Brokerage of Other Commodity |
|
Established (mm/dd/yyyy) |
03/30/1995 |
Mr. Oh Jang-Suck owns the
premises of registered HQ address.
Detailed Products
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Cosmetics(53131619) |
|
Sell |
Flavours or extracts(12164502) |
CEO’s
|
Name |
Oh Sung-Suck |
|
Address |
426, Apgujeong-dong ,Gangnam-gu, Seoul, Korea |
|
Date of Birth |
04/09/1955 |
|
Title |
President & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
Profiles
|
Capital |
50,000,000 KRW |
|
Employees |
12 |
|
Formation |
Co., Ltd by shares |
|
Bank Details |
N/A |
|
Corporate Registered No. |
110111-1143629 |
|
Business Registered No. |
120-81-49437 |
|
Permit & Licenses |
N/A |
|
Shareholder Position |
N/A |
|
Company History |
03/1983 Commencement of indenting business
under name of Sam-Oh Trading 05/1993 Change of company name into Sam-Oh
World Co., Ltd. 03/30/1995 Spin-off the company 03/30/1995 Sam-Oh Farmachem Co., Ltd. for
indenting business 05/1995 Sam-Oh World Co., Ltd. for import
and export, wholesale business 05/1999 Change of the name from Sam-Oh
World Co., Ltd. into Sam-Oh Pharm Co., Ltd. 05/1999 Purchasing of Sihwa Factory for
chemical synthesis (Address : Jeongwang-dong, Siheung-si, Gyonggido, Korea) 01/2001 Establishment of R&D Center 06/2001 Moved to the present HQ address
from 44-10, Samseong-dong ,Gangnam-gu, Seoul, Korea 07/2001 Re-construction of Sihwa Factory
for BGMP compliance 04/2002 BGMP-approved by KFDA 04/2002 KGSP-approved by KFDA 03/2003 Award of a prize “Exemplary
Obligor to Taxation” from the National Tax Service 10/2003 Nominated by “Korean Exchange
Bank(KEB) Prime Business Club” (club for the top-ranking company) 12/2004 CPHI Worldwide Brussels 2004 Booth
Exhibition 09/2005 DMF filing of several APIs to KFDA
06/2006 CPHI China 2006 Booth Exhibition 10/2007 CPHI Worldwide Milano 2007 Booth
Exhibition 05/2008 Award by Ministry for Health on
the "Pharmaceutical Export Day" |
Management
|
Job Description |
Title |
Name |
Sex |
Nationality |
Inauguration Day |
|
President & CEO |
Mr. |
Oh Sung-Suck |
Male |
Korean |
03/30/1995 |
|
Director |
M/S. |
Kim Mi-Kyung |
Female |
Korean |
03/30/2001 |
|
Director |
Mr. |
Oh Jang-Suck |
Male |
Korean |
03/30/1995 |
|
Auditor |
Mr. |
Won Kook-Jin |
Male |
Korean |
05/13/2005 |
Financials
Unit: KRW
The financial is not available, and the
subject does not have any obligation to releases its financials to the public.
Financial Description
Unit: KRW
|
Authorized
Capital |
200,000,000 |
|
Paid-Up
Capital |
50,000,000 |
|
Total Issues Shares |
5,000 |
Products, Technologies, Services
Description
|
Main
Products & Services |
APIs - Aceclofenac, Caroverine, Levosulpiride,
Tiropramide Cosmetics Health & Functional Foods Veterinary Pharmaceuticals Diagnostics |
Related Parties (Subsidiaries,
Joint-Venture & Affiliates)
|
|
SAM-OH PHARM
CO., LTD.(110111-0939540) SAEHAN PHARM.
CO., LTD.(134611-0001044) |
Sales by
Region (Activity &
Markets)
The Subject imports from China, Spain, Japan and UK.
Court
Action
Not Available.
News
Clipping
--
FOREIGN EXCHANGE
RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.46.63 |
|
UK Pound |
1 |
Rs.83.76 |
|
Euro |
1 |
Rs.66.49 |
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)